TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04365842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital exercise group
Description: Hand Rehabilitation Program: Developed hand exercise smartphone app which include: Self-assessment, (b) self-monitoring (c) exercises types/frequency/ diary, (d) patient education, (e) behavioral change and encouragement (f) exercise adherence Sample exercises~1. Hand and finger movements: 6-8 repetitions, according to the diagnosis of the patient~2. Strengthening exercises of hand and finger muscles~3. Exercises to increase grip and pinch strength~4. Exercises to increase tendon swing and pull angle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Home Hand Therapy
Description: Hand rehabilitation home program will be given to the through the telephone messages with brochures.~1. Hand and finger movements: 6-8 repetitions, according to the diagnosis of the patient~2. Strengthening exercises of hand and finger muscles~3. Exercises to increase grip and pinch strength~4. Exercises to increase tendon swing and pull angle
Study: NCT03519360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UFR-restricted dialysis
Description: UFR's are limited to a maximum of 10 mL/kg/hr for the duration of the session. In order to prevent progressive volume overload and the need for additional hemodialysis sessions to manage volume gains in this scenario, subjects will crossover weekly between the restricted and unrestricted UFR interventions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UFR-unrestricted dialysis
Description: UFR's will be unlimited and prescribed according to the standard of care.
Study: NCT03441958

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ECT-001 (UM171) expanded cord blood
Description: ECT-001 expanded cord-blood will be produced and infused on site
Study: NCT03891979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given for two doses every 3 weeks starting on day 8 (ie days 8 and 29). Antibiotics will continue throughout the entire four week pre-operative period.~Ciprofloxacin 500mg PO BID days 1-29; Metronidazole 500mg PO TID days 1-29; Pembrolizumab 200mg IV days 8 and 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500mg PO BID days 1-29
Description: Antibiotics will continue throughout the entire four week pre-operative period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 500mg PO TID days 1-29
Description: Antibiotics will continue throughout the entire four week pre-operative period.
Study: NCT00079963

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 1000 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: 800 IU/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03344991

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Open Crib
Description: When ready to be weaned from radiant warmer, infant will be placed in a standard of care open crib for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found \< 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
Study: NCT03695042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Training with Exercise
Description: The addition of BFR training to an exercise program prescribed for a patient participating in physical therapy for concussion treatment. BFR training partially occludes blood flow to extremities during exercise. This allows one to exercise at lower loads and still gain benefits similar to exercise at higher loads

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Training with Exercise
Description: The addition of BFR training to an exercise program prescribed for a patient participating in physical therapy for concussion treatment. BFR training partially occludes blood flow to extremities during exercise. This allows one to exercise at lower loads and still gain benefits similar to exercise at higher loads
Study: NCT02278601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: epidural delivery system
Description: epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: epidural delivery system
Description: epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: epidural delivery system
Description: epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
Study: NCT02908269

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative
Description: 0.5 mL, Intramuscular
Study: NCT03454334

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: multifocal intraocular lens IOLs
Description: clinical outcome of different multifocal intraocular lenses (IOLs) in patients with presbyopia or cataracts
Study: NCT02908269

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High-Dose, vaccine, 2016-2017 formulation
Description: 0.5 mL, Intramuscular
Study: NCT04057495

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: further fasting
Description: 2 hours of fasting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: white bread consumption
Description: 113 grams of white bread consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mango consumption
Description: 330 grams of mango consumption
Study: NCT00510666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline infusion adjunct to morphine PCA pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate
Description: Butorphanol was delivered at a continuous infusion manner adjunct to morphine PCA pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride
Description: 100mg tramadol was used preemptively to morphine PCA pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Preemptive saline as a control group to tramadol one
Study: NCT01204892

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Description: Patient will received bilateral ultrasound-guided TAP block with total of 30 ml of ropivacaine 0.5% after induction of general anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration
Description: 20 ml of Ropivacaine 0.5% will be injected at port sites after induction of general anesthesia. 7 ml each for 10 mm ports, 3 ml each of 5 mm ports
Study: NCT01407861

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Training
Description: Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic endurance Training
Description: Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
Study: NCT00399152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine Oral Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Sunitinib oral dose
Study: NCT00870779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid
Description: 20mg/kg 3 hours prior to surgery
Study: NCT02131298

Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib Alone
Description: A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection

Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib plus itraconazole
Description: Itraconazole 200 mg once daily with food for a total of 11 days; on Day 5, a single oral 125 mg dose of palbociclib will be given with itraconazole after a meal, followed by 168 hours of PK sample collection.
Study: NCT06531447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Every 21 days 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Every 21 days (First and 8th days) 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Every 21 days 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Every 21 days 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Every 21 days 4 cycles or once a week for 12 weeks
Study: NCT00920192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foretinib
Description: Phase I starting dose 30 mg/day escalated to 45 mg/day; de-escalated to 30 mg/day. MTD for Phase II dose was 30 mg/day,
Study: NCT02516059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone/naloxone
Description: Oxycodone and naloxone (Targin®; Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10mg/5mg on POD 3 and move to 20mg/10mg the other day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone (Oxycontin®, Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10 mg on POD 3 and move to 20 mg the other day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: epidural catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: epidural catheter

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: epidural catheter
Study: NCT00766415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: Oral tablet, twice daily, 4 weeks treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02755935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Nucleus CI532
Description: cochlear implantation
Study: NCT04479891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib tablet
Description: single oral dose of SHR6390 or co-administered with itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole capsule
Description: 200 mg itraconazole QD
Study: NCT02041182

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Visit Questionnaire

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Visit Questionnaire
Study: NCT02825394

Intervention type: OTHER
Intervention: anti-Xa activity point-of-care testing (aXa-POCT)

Intervention type: OTHER
Intervention: anti-Xa activity point-of-care testing (aXa-POCT)

Intervention type: OTHER
Intervention: anti-Xa activity point-of-care testing (aXa-POCT)

Intervention type: OTHER
Intervention: anti-Xa activity point-of-care testing (aXa-POCT)

Intervention type: OTHER
Intervention: anti-Xa activity point-of-care testing (aXa-POCT)
Study: NCT03454334

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: multifocal intraocular lens IOLs
Description: clinical outcome of different multifocal intraocular lenses (IOLs) in patients with presbyopia or cataracts

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: multifocal intraocular lens IOLs
Description: clinical outcome of different multifocal intraocular lenses (IOLs) in patients with presbyopia or cataracts

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: multifocal intraocular lens IOLs
Description: clinical outcome of different multifocal intraocular lenses (IOLs) in patients with presbyopia or cataracts
Study: NCT04468568

Intervention type: DRUG
Intervention: Atosiban
Description: Atosiban intravenous. Dose: attack of 6.75 mg, and maintenance of 300 mcg / min for 3 hours, and 100 mcg / min for 21 hours.
Study: NCT03172390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4D Cardiac Magnetic Resonance
Description: 4D Cardiac Magnetic Resonance for patients with a ascending aorta dilatation without current indication for surgery for measured parameters of ascending aorta
Study: NCT02825394

Intervention type: OTHER
Intervention: anti-Xa activity point-of-care testing (aXa-POCT)

Intervention type: OTHER
Intervention: ecarin clotting time point-of-care testing (ECT-POCT)
Study: NCT03347227

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Wide area circumferential catheter ablation for pulmonary vein isolation of persistent atrial fibrillation
Study: NCT02825394

Intervention type: OTHER
Intervention: ecarin clotting time point-of-care testing (ECT-POCT)
Study: NCT04592692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGylated Liposome (PEGLip)
Description: Intravenous co-administration of PEGLip with Simoctocog alfa

Intervention type: DRUG
Group type: OTHER
Intervention: PEGylated Liposome (PEGLip)
Description: Intravenous co-administration of PEGLip with Simoctocog alfa
Study: NCT03347227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Wide area circumferential catheter ablation for pulmonary vein isolation of persistent atrial fibrillation
Study: NCT01898195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline will be provided for three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline will be provided for three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline will be provided for three months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Text messages will be developed twice daily for three months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Text messages will be developed twice daily for three months
Study: NCT04569123

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real stimulation
Description: Participants will undergo standardized hand task practice therapy (3 sessions/week for 6 weeks) with the watch worn on the paretic wrist. Participants will be randomized into two groups: The device will deliver vibration for the treatment group.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: No stimulation
Description: Participants will undergo standardized hand task practice therapy (3 sessions/week for 6 weeks) with the watch worn on the paretic wrist. Participants will be randomized into two groups: The device will deliver no vibration for the control group during therapy.
Study: NCT00764816

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: grain (soy) protein diet
Description: The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: casein (meat) protein diet
Description: The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
Study: NCT01898195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Behavioral Therapy
Description: Seven Adherence Behavioral Therapy sessions will given over a three month period
Study: NCT03457259

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVC and/or PICCline
Description: Pt. will receive PVC and/or PICCline

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Midline
Description: Pt. will receive midline
Study: NCT02278276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium polysulthionate
Description: Bioavailable composition of α-sulfur

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg capsules containing placebo
Study: NCT00389935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 50 - 200 mg once at nightime
Study: NCT04468568

Intervention type: DRUG
Intervention: Terbutaline
Description: Terbutaline intravenous. Dose: 2.5 mg in 500 mL saline, infusion rate of 30 mL / hr (150 mcg / h) during the surgery and for 24 hours.
Study: NCT04306731

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nanotechnology Structured water Magnalife
Description: Nanotechnology Structured water Magnalife is drinking water that has been modified using nanotechnology to change the structuring of water molecules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim
Description: Antibiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ordinary bottled drinking water
Description: Placebo
Study: NCT02897778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entinostat
Description: Single, supratherapeutic dose of entinostat given orally.
Study: NCT01528046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine (VCR) = 1.5 mg/m\^2/day (maximum dose 2 mg), days 1 and 8, administered as intravenous (IV) bolus over 1-5 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan (IRN) = 50 mg/m\^2/day, days 1-5, IV over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (TEM) = 50 mg/m\^2/day by mouth (PO) Days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin (MET) = dose as per dose escalation, divided twice a day (BID), PO continuously for the 21 day cycle.
Study: NCT02147262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline orally, 100 mg, bid, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline orally, 100 mg, bid, 28 days
Study: NCT00984828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velcade
Description: velcade 1.3mg/m2 D1, 4, 8 and 11

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: velcade
Description: velcade 1.3mg/m2 D1, 4, 8 and 11
Study: NCT03287102

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Macular hole surgery
Description: Vitrectomy, temporal inverted or complete ILM peeling and gas tamponade

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Macular hole surgery
Description: Vitrectomy, temporal inverted or complete ILM peeling and gas tamponade
Study: NCT00552682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg, QD
Description: Duloxetine 60 mg, 1 table/day, 1 year
Study: NCT03794999

Intervention type: DRUG
Intervention: Benralizumab-exposure
Description: Exposure is defined as any dose of benralizumab for any length of time from 8 weeks prior to Last Mentrual Period (LMP) through the end of pregnancy, as reported by the mother and validated through medical record review. The 8-week cut-off prior to LMP is based upon the terminal half-life of benralizumab of approximately 15 days (clearance of benralizumab is based on five half-lives).

Intervention type: DRUG
Intervention: Exposure to other asthma medications
Description: Exposure to asthma medications for any number of days, at any dose, and at any time from LMP up to the date of enrollment, but no exposure to benralizumab during pregnancy or within 8 weeks prior to LMP.
Study: NCT03596879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dCBTI
Description: Online access to the digital CBTI program Sleepio based off of traditional face-to-face Cognitive Behavioral Therapy, six weekly sessions done online.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Education
Description: Six weekly email messages with sleep hygiene recommendations. Subjects are encouraged to read through the information and apply it to their sleep.